Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood-based biomarker discovery in motor neuron disease using nucleic acid-linked immuno-sandwich assay.

Brain communications·2026
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

The World Brain Health Forum: breaking silos for co-ordinated action.

Nature reviews. Neurology·2026
Same author

Redefining the norms: an interdisciplinary perspective on language testing in multilinguals with acquired and progressive neurogenic disorders.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Lancet (London, England)·2026
Same author

Catalysing a united response in Europe for neurodegenerative diseases: CURE-ND.

The Lancet. Neurology·2026
Same journal

Social Determinants of Health and Their Association With Parkinson's Disease Prevalence in US Adults: Insights From NHANES 2001-2020.

Behavioural neurology·2026
Same journal

GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius.

Behavioural neurology·2026
Same journal

Using Virtual Reality to Complement Paper-and-Pencil Tests to Assess Visual Unilateral Spatial Neglect: A Feasibility Study.

Behavioural neurology·2026
Same journal

Adverse Childhood Experiences Underlie Race-Related Differences in Neural Reactivity to Stress.

Behavioural neurology·2026
Same journal

The Clinical Effect of Annonaceae Fruit Consumption on Caribbean Parkinson's Disease Severity.

Behavioural neurology·2026
Same journal

Mind the Gap: A Systematic Review of Borderline Intellectual Functioning in Childhood and Adolescence.

Behavioural neurology·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Patterns of cognitive dysfunction in progressive MS.

Peter Connick1, Siddharthan Chandran, Thomas H Bak

  • 1Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Behavioural Neurology
|April 4, 2013
PubMed
Summary
This summary is machine-generated.

Cognitive impairment in progressive multiple sclerosis (MS) involves both global dysfunction and specific deficits, particularly in language and visuospatial functions. Early assessment of these abilities is crucial for effective clinical management.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Related Experiment Videos

Last Updated: May 12, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Area of Science:

  • Neuroscience
  • Neurology
  • Cognitive Science

Background:

  • Progressive multiple sclerosis (MS) frequently causes cognitive impairment, but the nature of this dysfunction (global vs. specific deficits) remains unclear.
  • Understanding cognitive patterns is vital for managing progressive MS, impacting patient quality of life and disease progression.

Purpose of the Study:

  • To characterize cognitive impairment patterns in progressive MS using a comprehensive assessment tool.
  • To differentiate between global cognitive decline and specific functional deficits in progressive MS patients.

Main Methods:

  • Utilized the Addenbrooke's Cognitive Examination-Revised (ACE-R) to assess patients with secondary progressive MS (SPMS) and primary progressive MS (PPMS).
  • Employed factor analysis to identify independent dimensions of cognitive impairment and their contribution to overall dysfunction.

Main Results:

  • Identified two primary dimensions of cognitive impairment: frontal-executive functions (attention, verbal fluency, recall) and language/visuospatial functions.
  • Frontal-executive deficits were underrepresented in SPMS and absent in PPMS, while language and visuospatial deficits were common in both groups.
  • Global cognitive influence accounted for 14.2% of total variance, with frontal-executive and language/visuospatial dimensions explaining 55% and 45% of the remaining variance, respectively.

Conclusions:

  • Progressive MS is characterized by a significant global cognitive impact alongside common language and visuospatial deficits.
  • Clinical evaluations for progressive MS should incorporate assessments of language and visuospatial abilities to capture the full spectrum of cognitive impairment.